Abstract 3694: Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed refractory multiple myeloma (RRMM) patients
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-3694
Abstract: ISB 2001 is the first trispecific antibody that simultaneously targets BCMA and CD38 on MM cells, and CD3 to engage T-cells, forming tumor/immune cell synapses (TICS) that cause tumor cytotoxicity. Since ISB 2001 lacks cross-reactivity… read more here.
Keywords: pharmacology; fih dose; isb 2001; model ... See more keywords
Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.7514
Abstract: 7514 Background: MM remains an incurable disease and resistance mechanisms are emerging. ISB 2001, a first-in-class trispecific T cell engager, redirects cytotoxic T cells to BCMA and/or CD38-expressing myeloma cells. By simultaneously targeting two TAA,… read more here.
Keywords: isb; dose escalation; isb 2001; myeloma ... See more keywords